[1]
عبدالله .ن. 2022. Evaluation of the efficacy of bevacizumab in recurrence metastatic ovarian cancer as a second-line and beyond. Tishreen University Journal -Medical Sciences Series. 44, 1 (Mar. 2022), 49–57.